Exenatide
Effects of GLP-1 RAs on Weight and Metabolic Indicators in Obese Patients
AstraZeneca · Phase 3 · Status n/r · Enrollment 150
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Liraglutide | Obesity or overweight | n/r | 4 | n/r | n/r |
| Exenatide | Obesity or overweight | n/r | 4 | n/r | n/r |
| Exenatide Microspheres for Injection | Obesity or overweight | n/r | 4 | n/r | n/r |